

Special Issue

New Insights into Surgical Treatment of Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma (HCC) stands as the sixth most common cancer and the fourth most common cause of cancer-related death worldwide. Curative treatments are applicable in a minority of selected patients. HCCs most likely arise from chronic liver diseases; thus, liver transplantation theoretically offers the best chances of a cure. However, the broad use of transplantation for HCC faces various constraints, advocating for surgical resection as one of the preferred options provided there is adequate patient selection and anticipation of the postoperative risk of liver failure. With this Special Issue in *Cancers*, we welcome original pre-clinical or clinical research articles and comprehensive or systematic reviews focusing on the surgical treatment of HCC through the spectrum of evolving tools, strategies, indications, and techniques.

Guest Editor

Dr. Christian Hobeika

1. Departement of HPB Surgery and Liver Transplantation, Beaujon Hospital, APHP, Clichy, Paris-Cité University, Paris, France
2. UMR Inserm 1275 CAP Paris-Tech, Lariboisière Hospital, Paris-Cité University, Paris, France
3. Toronto Organ Preservation Laboratory, Department of Multi Organ Transplant, University Health Network, Toronto, ON, Canada

Deadline for manuscript submissions

closed (31 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/168994

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)